Preview

Аналоги инсулина пролонгированного действия: сравнительная характеристика строения, фармакологических свойств, возможностей клинического применения

https://doi.org/10.14341/probl201056264-71

Об авторе

N Berbovaia



Список литературы

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.

2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.

3. Riddle M.C. Timely initiation of basal insulin. Am J Med 2004; 116 (Suppl 3A):3S-9S.

4. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2008; 51: 8-11.

5. Hoogma R.P., Hammond P.J., Gomis R. et al. 5-Nations Study Group: Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-Nations Trial. Diabet Med 2006; 23: 141-147.

6. Heinemann L., Linkeschova R., Rave K. et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.

7. Fanelli G.C., Pampanelli S., Porcellati F. et al. Administration of neutral protamine Hagedorn insulin at bedtime versus dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann Intern Med 2002; 136: 504-514.

8. Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.

9. Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcuta­neous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.

10. Heise T., Nosek L., Rønn B.B. et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.

11. Klein O., Lynge J., Endahl L. et al. Albumin-bound basal insulin analogs (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.

12. Porcellati F., Rossetti P., Busciantella Ricci N. et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after one week of use as compared to its first administration in subjects with Type 1 diabetes mellitus. Diabetes Care 2007; 30: 1261-1263.

13. Porcellati F., Rossetti P., Busciantella S. et al. Comparison of pharmacokinetics and -dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care 2007; 30: 2447-2452.

14. Rosskamp R.H., Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 (Suppl 2): B109-B113.

15. Berchtold H., Hilgenfeld R. Binding of phenol to R6 insulin hexamers. Biopolymers 1999; 51: 165-172.

16. Owens D.R., Coates P.A., Luzio S.D. et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-819.

17. Kuerzel G.U., Shukla U., Scholtz H.E. et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19: 34-40.

18. Peter R., Luzio S.D., Dunseath G. et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care 2005; 28: 560-565.

19. Barlocco D. Insulin detemir. Novo Nordisk. Curr Opin Investig Drugs 2003; 4: 449-454.

20. Havelund S., Plum A., Ribel U. et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-1504.

21. Kurtzhals P., Schäffer L., Sørensen A. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.

22. Radziuk J., Pye S., Bradley B. et al. Basal activity profiles of NPH and [Ne-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 1998; 41: 116-120.

23. Hordern S.V., Wright J.E., Umpleby A.M. et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycemic clamp. Diabetologia 2005; 48: 420-426.

24. Rossetti P., Porcellati F., Busciantella Ricci N. et al. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 2008; 57: 746-756.

25. Heinemann L., Sinha K., Weyer C. et al. Time-action profile of the soluble, fatty acid acy-lated, long-acting insulin analog NN304. Diabet Med 1999; 16: 332-338.

26. Brunner G.A., Sendhofer G., Wutte A. et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analog NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000; 108: 100-105.

27. Plank J., Bodenlenz M., Sinner F. et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.

28. Hompesch M., Troupin B., Heise T. et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006; 8: 568-573.

29. Wutte A., Plank J., Bodenlenz M. et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007; 115: 461-467.

30. Ciaraldi T.P., Carter L., Seipke G. et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001; 86: 5838-5847.

31. Hansen B.F., Danielsen G.M., Drejer K. et al. Sustained signalling from the insulin receptor after stimulation with insulin analogs exhibiting increased mitogenic potency. Biochem J 1996; 315: 271-279.

32. Staiger K., Staiger H., Schweitzer M.A. et al. Insulin and its analogue glargine do not affect variability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48: 1898-1905.

33. Staiger K., Hennige A.M., Staiger H. et al. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2006; 39: 65-67.

34. Erbel S., Reers C., Eckstein V.W. et al. Proliferation of Colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma is not altered by insulin glargine. Diabetes Care 2008; 31: 1105-1111.

35. Hennige A.M., Sartorius T., Tschritter O. et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006;49:1274-1282.

36. Carvalheira J.B., Ribeiro E.B., Araujo E.P. et al. Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 2003; 46: 1629-1640.

37. Niswender K.D., Morrison C.D., Clegg D.J. et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 2003; 52: 227-231.

38. Hermansen K., Davies M., Derezinski T. et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.

39. Home P., Kurtzhals P. Insulin detemir: from concept to clinical experience. Exp Opin Pharmacother 2006; 7: 325-343.

40. Fritsche A., Häring H. At last, a weight-neutral insulin? Int J Obes 2004; 28(Suppl 2): S41-S46.

41. Hermansen K., Fontaine P., Kukolja K.K. et al. Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.

42. Pieber T.R., Draeger E., Kristensen A., Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.

43. Standl E., Lang H., Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.

44. De Leeuw I., Vague P., Selam J.L. et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.

45. Bartley P.C., Bogoev M., Larsen J., Philoteous A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals. A 2-year, randomized, controlled trial. Diabet Med 2008; 25: 442-444.

46. Bush M.A. Intensive diabetes therapy and body weight: focus on insulin detemir. Endocrinol Metab Clin North Am 2007;36(Suppl 1):33-44.

47. Rosenstock J., Fonseca V., McGill J. et al. Similar progression of di­abetic retinopathy with glargine or NPH insulin in Type 2 diabetes [abstract 301-OR]. Diabetes 2008; 57(Suppl 1): A86.

48. Davis M.D., Beck R.W., Home P.D. et al. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. Exp Clin Endocrinol Diabetes 2007; 115: 240-243.

49. Andres R., Swerdloff R., Pozefsky T., Coleman D. Manual feedback technique for the control of blood glucose concentration. In: Skeggs L, ed. Automation in Analytical Chemistry. White Plains, NY: Mediad Inc., 1966: 486-491.

50. Heinemann L., Anderson J.H. Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004; 6: 698-718.

51. Luzio S.D., Beck P., Owens D.R. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Horm Metab Res 2003; 35: 434-438.

52. Gerich J., Becker R.H.A., Zhu R., Bolli G.B. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 2006; 8: 237-243.

53. Bolli G.B., Di Marchi R.D., Park G.D. et al. Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.

54. Mucha G.T., Merkel S., Thomas W., Bantle J.P. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care 2004; 27: 1209-1210.

55. Hamann A., Matthaei S., Rosak C., Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744.

56. Ashwell S.G., Gebbie J., Home P.D. Twice-daily compared with once-daily glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006; 23: 879-886.

57. Bruttomesso D., Crazzolara D., Maran A. et al. In Type 1 diabetic patients with good metabolic control blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with glargine. Diabet Med 2008; 25: 326-332.

58. Garg S.K., Walker A.J., Hoff H.K. et al. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004; 6: 9-15.

59. Lepore G., Dodesini A.R., Nosari I., Trevisan R. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study. Diabetes Nutr Metab 2004; 17: 84-89.

60. Bolli G.B., Capani F., Home P.D. et al. Comparison of a multiple daily injection regimen with once-daily insulin glargine basal insulin and mealtime lispro, to continuous subcutaneous insulin infusion: a randomised, open, parallel study [abstract]. Diabetes 2004; 53: A107.

61. Eliaschewitz F.G., Calvo C., Valbuena H. et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495-501.

62. Massi Benedetti M.M., Humburg E., Dressler A., Ziemen M. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.

63. Pan C.-Y., Sinnassamy P., Chung K.-D., Kim K.-W. LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007; 76: 111-118.

64. Riddle M.C., Rosenstock J., Gerich J. Insulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.

65. Rosenstock J., Schwartz S.L., Clark C.M. Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.

66. Yki-Jarvinen Т., Dressler A., Ziemen M. HOE 901/3002 Study Group. HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-1136.

67. Bott S., Tusek C., Jacobsen L.V. et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med 2006; 23: 522-528.

68. Meneghini L.F., Rosenberg K.H., Koenen C. et al. Insulin detemir improves glycemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9: 418-427.

69. Hompesch M., Troupin B., Heise T. et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006; 8: 568-573.

70. Vague P., Selam J.L., Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.

71. Russell-Jones D., Simpson R., Hylleberg B. et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.

72. Hermansen K., Madsbad S., Perrild H. et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.

73. Home P., Bartley P., Russell-Jones D. et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.

74. Rosenstock J., Davies M., Home P.D. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51: 408-416.

75. Alvarez de Guisasola F., Casal Llorente C., Rubio-Terrs C. Costs analysis of type 2 diabetes mellitus treatment with glargine insulin or detemir insulin in Spain. Rev Esp Econ Salud 2007; 6: 304-310.

76. Johnson C.K., Shimshi M. When is a unit of insulin not a unit of insulin? Detemir dosing in type 2 diabetes [abstract 8-LB]. http://professional.diabetes.org/UserFiles/ (accessed June 29, 2008).


Для цитирования:


. Аналоги инсулина пролонгированного действия: сравнительная характеристика строения, фармакологических свойств, возможностей клинического применения. Проблемы Эндокринологии. 2010;56(2):64-71. https://doi.org/10.14341/probl201056264-71

For citation:


Berbovaia N.I. Long-acting insulin analogues: comparative characteristics of their structure, pharmacological properties, and potential for clinical application. Problems of Endocrinology. 2010;56(2):64-71. (In Russ.) https://doi.org/10.14341/probl201056264-71

Просмотров: 54


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)